Galectin-1 inhibits oral-intestinal allergy syndrome

Autor: Shuai Wang, Qi Liu, Zhigang Liu, Ling-Zhi Xu, Li-Tao Yang, Ping-Chang Yang, Rui-Di Xie
Rok vydání: 2017
Předmět:
Zdroj: Oncotarget
ISSN: 1949-2553
Popis: // Rui-Di Xie 1, 2, * , Ling-Zhi Xu 1, * , Li-Tao Yang 3, 4, * , Shuai Wang 3 , Qi Liu 2 , Zhi-Gang Liu 1 , Ping-Chang Yang 1 1 The Research Center of Allergy & Immunology, Shenzhen University School of Medicine, Shenzhen, China 2 Periodontal Department, the Affiliated Hospital of Zunyi Medical College, Zunyi, China 3 The ENT Hospital of Shenzhen University and Shenzhen ENT Institute, Shenzhen, China 4 Brain Body Institute, McMaster University, Hamilton, ON, Canada * These authors contributed equally to this work Correspondence to: Ping-Chang Yang, email: pcy2356@szu.edu.cn Zhi-Gang Liu, email: lzg@szu.edu.cn Qi Liu, email: liuqi1964@hotmail.com Keywords: oral mucosa, oral allergy, peanut, micro RNA-98, galectin-1 Received: August 25, 2016 Accepted: December 27, 2016 Published: January 10, 2017 ABSTRACT Background and aims: The pathogenesis of oral-intestinal allergy syndrome (OIAS) has not been well understood. Published data indicate that galectin (Gal) 1 has immune regulatory functions. This study tests a hypothesis that Gal1 inhibits oral-intestinal allergy syndrome. Methods: Mice were sensitized to peanut extracts (PE) via the buccal mucosa with or without using Gal1 together. Results: Upon re-exposure to specific antigen, the OIAS mice showed the systemic allergic response, the oral allergic reactions, and intestinal allergic inflammation, including increases in serum histamine, drop of the core temperature, higher levels of PE-specific IgE and interleukin (IL)-4. Increases in mast cell and eosinophil in the oral mucosa and intestinal mucosa were also observed. The OIAS was inhibited by co-administration with Gal1 via a mechanism of suppressing micro RNA (miR)-98 and reversing the expression of IL-10 in CD14+ cells in the intestine. Conclusions: The OIAS can be induced by applying specific antigens to the oral mucosa, which can be inhibited by co-administration with Gal1.
Databáze: OpenAIRE